Education
About Us
Working with TipRanks
Follow Us
Passage Bio (PASG)
NASDAQ:PASG
PASG Stock Chart & Stats
$18.33
>-$0.01(-0.86%)
At close: 4:00 PM EST
$18.33
>-$0.01(-0.86%)
Day’s Range― - ―
52-Week Range$5.12 - $19.25
Previous CloseN/A
Volume182.24K
Average Volume (3M)41.18K
Market Cap
$57.20M
Enterprise Value-$2.91M
Total Cash (Recent Filing)$52.77M
Total Debt (Recent Filing)$24.34M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Mar 09, 2026EPS Estimate
-2.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding3,120,295
10 Day Avg. Volume55,130
30 Day Avg. Volume41,182
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.56
Price to Sales (P/S)0.00
P/FCF Ratio-0.71
Enterprise Value/Market Cap-0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.17
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$40.33Price Target Upside120.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker EvidenceRobust elevation of progranulin in cerebrospinal fluid and stabilization of neurofilament light chain offer direct biological evidence that PBFT02 engages its target and may slow neurodegeneration in GRN-related FTD.
Manufacturing ComparabilityAgreement on how to demonstrate comparability between clinical- and commercial-scale manufacturing lowers scale-up risk and supports readiness for broader production if clinical results are positive.
Regulatory PathwayAlignment with regulators on a single-arm registrational design for a high unmet medical need increases the likelihood of a streamlined approval pathway for PBFT02.
Bears Say
Regulatory Scrutiny And CostSafety signals could prompt regulators to request additional studies or data, increasing the chance of a lengthier and more expensive approval process for the asset.
Serious Adverse EventA pulmonary embolism reported as a serious adverse event and the resulting amended safety protocol highlight material safety concerns that could weaken confidence in the program.
Trial Timeline And Enrollment RiskOccurrence of multiple serious adverse events may trigger increased monitoring and slower patient recruitment, risking delays to pivotal trials and higher development costs.
Passage Bio News
PASG FAQ
What was Passage Bio’s price range in the past 12 months?
Passage Bio lowest stock price was $5.12 and its highest was $19.25 in the past 12 months.
What is Passage Bio’s market cap?
Passage Bio’s market cap is $57.20M.
When is Passage Bio’s upcoming earnings report date?
Passage Bio’s upcoming earnings report date is Mar 09, 2026 which is in 57 days.
How were Passage Bio’s earnings last quarter?
Passage Bio released its earnings results on Nov 18, 2025. The company reported -$2.44 earnings per share for the quarter, beating the consensus estimate of -$2.758 by $0.318.
Is Passage Bio overvalued?
According to Wall Street analysts Passage Bio’s price is currently Undervalued.
Does Passage Bio pay dividends?
Passage Bio does not currently pay dividends.
What is Passage Bio’s EPS estimate?
Passage Bio’s EPS estimate is -2.57.
How many shares outstanding does Passage Bio have?
Passage Bio has 3,120,295 shares outstanding.
What happened to Passage Bio’s price movement after its last earnings report?
Passage Bio reported an EPS of -$2.44 in its last earnings report, beating expectations of -$2.758. Following the earnings report the stock price went down -7.512%.
Which hedge fund is a major shareholder of Passage Bio?
Currently, no hedge funds are holding shares in PASG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Passage Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.33 (120.02% Upside)
$40.33 (120.02% Upside)
Hedge Fund Trend
Decreased
By 37.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.84%
12-Months-Change
Fundamentals
Return on Equity
-87.18%
Trailing 12-Months
Asset Growth
-33.64%
Trailing 12-Months
Company Description
Passage Bio
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
PASG Stock 12 Month Forecast
Average Price Target
$40.33
▲(120.02% Upside)
Technical Analysis
Tempest Therapeutics
―
Chemomab Therapeutics
―
Annovis Bio
―
Generation Bio
―
Cognition Therapeutics
―
Ownership Overview
Currently, No data available
---